Circulatory System Nutritional, Metabolic, Endocrine Cardiology
Conditions
Interventions
Sponsors
Luscii App
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Age =18 years - Confirmed hypertension with BP>140/90 mmHg - Own or have access to a smartphone with internet access throughout the study period - Able to provide written informed consent prior to participation in the study
Exclusion criteria
Exclusion criteria: - Persistent atrial fibrillation as indicated in the health record - Pregnant or planning to become pregnant during the study period - Severe kidney disease, defined as estimated glomerular filtration rate <30 per 1.73 m2 or currently on renal replacement therapy (i.e., hemodialysis or peritoneal dialysis) - Recent cardiovascular event (ischemic stroke, transient ischemic attack, myocardial infarction, coronary artery bypass grafting) in the past 3 months - Diagnosis of dementia or psychosis as indicated in the health record - Life expectancy <1 year, for instance in terminal cancer or NYHA III or IV heart failure - Individuals requiring BP monitor cuff size larger than 42cm
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HBPT will improve hypertension control rates (% below <140/90mmHg, as measured by the SPRINT protocol) at 6 months as compared with historical nationwide hypertension control rates. | — |
Secondary
| Measure | Time frame |
|---|---|
| HBPT will improve drug adherence (as measured with the MARS-5 tool) as compared with historical nationwide drug adherence data.;Digital application of Kenya’s national cardiovascular disease guidelines will lead to improved guideline adherence as measure by ‘guideline-based prescriptions’ compared with baseline.;Patient satisfaction in the HBPT program will be high based on TUQ and MAUQ questionnaires (overall median >5, scale 1 to 7) | — |
Countries
Kenya
Contacts
Public ContactKennedy Okinda
Study Coordinator
Outcome results
None listed